Stockreport

Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Protei...

Savara, Inc.  (SVRA) 
Last savara, inc. earnings: 3/12 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: savarapharma.com/investors/events-presentations
PDF -- Company Remains on Track to Submit the Marketing Authorization Application (MAA) in Europe by the End of 2025 -- LANGHORNE, Pa., March 26, 2025 BUSINESS WIRE Savar [Read more]